From discovery to technological asset
Our portfolio brings together molecules developed through the PRISMA® Platform, selected based on computational and laboratory evidence and prepared to advance through co-development, licensing, or technology transfer.
Each asset starts with a concrete challenge and advances with a focus on industrial application.
PRISMA Agro IR-01
Plant resistance induction
Bioactive molecule developed to activate plants’ natural defense mechanisms and support more precise and sustainable crop protection strategies.
Stage: Patent
Application: Crop protection
PRISMA Agro F-01
Plant pathogen control
Peptide designed to act against fungi and bacteria relevant to agriculture, with development tailored to the sector’s technical and production needs.
Stage: Patent
Application: Agriculture
PRISMA Food Safety S-01
Microbiological food safety
Technology asset developed to control Salmonella and other microorganisms relevant to the food production chain, including activity against biofilms.
Stage: Patent
Application: Food and animal protein industries.
PRISMA Human Health AM-01
Antimicrobial for human health
Bioactive peptide developed through molecular engineering to act against microorganisms of clinical interest. The asset demonstrated antimicrobial activity in laboratory validation, alongside favorable toxicological results in computational analyses.
Stage: In vitro and in silico validation
Potential application: Development of new antimicrobial solutions
Partnership model: Co-development, licensing, or technology transfer
Different paths to turn technology into products
Co-development;
Validation in industrial settings;
Licensing;
Technology transfer;
Development of new molecules on demand.
Protected technology. Collaborative development.
The information presented provides a non-confidential overview of our portfolio. Detailed technical data are shared on a confidential basis and according to the stage of each negotiation.
Is your company facing a challenge that still needs the right molecule?
Talk to HYH about co-development, validation, licensing, or technology transfer.